‌

Actions

Action Type

‌
‌

AI Mode

Get instant AI-powered insights about company performance, financials, and strategy. Ask questions about trends, competition, and developments while receiving responses backed by official documents and market data, with clear attribution to source documents.

Ask AI

Overview

Detailed Summary

Torrent Pharmaceuticals is an India‑headquartered, vertically integrated pharmaceutical company focused on branded chronic and sub‑chronic therapies, with a diversified international presence across the US, Europe (Germany) and Latin America (Brazil) and over 15 country subsidiaries supporting formulation manufacturing, R&D and commercial operations for both regulated and emerging markets.
In Q3 FY26 Torrent reported consolidated revenues of INR 3,303 crore, up 18% year‑on‑year, with Operating EBITDA of INR 1,088 crore and an operating margin of 32.9%. Branded markets contributed roughly 75% of revenues; India grew 14% and Brazil grew 27%, while the U.S. and Germany contributed double‑digit and modest growth respectively amid some supply constraints.
Torrent acquired a controlling stake in JB Pharma in January and began line‑by‑line consolidation; management expects INR 400–450 crore of cost synergies over 2–3 years (20% in year one, majority thereafter) and a 6–9 month timeline to integrate post NCLT merger, making the JB acquisition a material near‑term strategic catalyst for the company.
Brazil represents a high‑conviction growth opportunity with a prioritized Semaglutide (GLP‑1) filing; management reports ANVISA prioritization and a 60‑molecule pipeline, but cautions on unpredictable approval timing and potential pricing erosion, which could meaningfully influence Brazilian revenue upside upon launch.
Near‑term operational risks include regulatory and third‑party supplier disruptions in Germany that depressed constant‑currency sales; the U.S. business is small but supported by a launch pipeline with management targeting annualized U.S. revenues near $200 million over the medium term, contingent on timely approvals and competitive dynamics.

Sector: Pharmaceuticals & Biotechnology
Industry: Pharmaceuticals
Market Cap: 1,95,129 Cr
Volatility: Low Risk
P/E Ratio: 91.3
Industry P/E: 37.4
PEG Ratio: 4.1
P/B Ratio: 22.0
52W High: 5,084.85
52W Low: 3,480.00

Sales CAGR

1Y: 67.37%
3Y: 11.66%
5Y: 10.68%
10Y: 9.87%

Profit CAGR

1Y: 11.87%
3Y: 27.74%
5Y: 14.01%
10Y: 11.04%

ROE

TTM: 25.49%
3Y: 17.89%
5Y: 17.55%
10Y: 17.62%

ROCE

TTM: 13.85%
3Y: 15.91%
5Y: 16.93%
10Y: 16.83%

Technicals

‌

Forecasts

Unlock more with professional

Analyst Target, Price, EPS and Revenue Projections
Get In-depth insights on EPS and Revenue forecasts

Peers

Healthcare Healthcare Pharmaceuticals

Symbol	Watchlist	Price	Market Cap	P/E	P/B	Div Yield (%)	ROE (%)	ROCE (%)	ROA (%)
DIVISLAB		7840.50	2,08,141 Cr	81.05	12.42	0.38	15.32	19.56	12.82
TORNTPHARM		4870.00	1,85,264 Cr	86.65	22.03	0.69	25.49	13.85	4.82
CIPLA		1464.00	1,18,430 Cr	35.14	3.44	0.89	11.27	14.95	7.92
ZYDUSLIFE		1113.75	1,11,272 Cr	22.08	4.10	0.09	18.59	17.35	9.59
LUPIN		2422.00	1,10,609 Cr	20.74	4.93	0.74	23.76	24.88	13.96
MANKIND		2576.95	1,06,427 Cr	55.64	6.53	0.04	11.74	13.13	6.90
LAURUSLABS		1784.75	96,251 Cr	88.03	18.16	0.11	16.77	16.14	10.38
Median: 7 Co.	—	2422.00	1,11,272 Cr	55.64	6.53	0.38	16.77	16.14	9.59

Financial Statements

AI Powered Summary

Discover detailed, AI-driven financial summaries that break down key metrics, trends, and insights—empowering you to make smarter investment decisions.

Ask AI

Consolidated Quarterly Results (in ₹ Crores)

View Standalone

Total Figures

QoQ Changes

Total Figures

	Mar 2024	Jun 2024	Sep 2024	Dec 2024	Mar 2025	Jun 2025	Sep 2025	Dec 2025	Mar 2026	Jun 2026
Sales	2,745	2,859	2,889	2,809	2,959	3,178	3,302	3,303	4,197	4,921
Expenses	1,862	1,955	1,950	1,895	1,995	2,146	2,219	2,215	2,841	3,257
Operating Profit	883	904	939	914	964	1,032	1,083	1,088	1,356	1,664
OPM %	32.17	31.62	32.50	32.54	32.58	32.47	32.80	32.94	32.31	33.81
Other Income	31	24	-16	33	-42	-37	-40	-23	-83	-33
Interest	80	75	64	57	56	56	48	45	236	305
Depreciation	203	197	198	199	201	201	204	206	508	593
Profit Before Tax	631	656	661	691	665	738	791	814	529	733
Tax %	28.84	30.34	31.47	27.21	25.11	25.75	25.28	21.99	31.19	22.78
Net Profit	449	457	453	503	498	548	591	635	364	566
EPS in Rs	13.27	13.51	13.37	14.88	14.71	16.19	17.54	18.77	11.51	—

Consolidated Profit Loss (in ₹ Crores)

View Standalone

Total Figures

YoY Changes

Total Figures

	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026	TTM
Sales	5,857	5,950	7,673	7,939	8,005	8,508	9,620	10,728	11,516	13,980	15,723
Expenses	4,480	4,601	5,690	5,769	5,524	6,077	6,778	7,360	7,795	9,421	10,532
Operating Profit	1,377	1,349	1,983	2,170	2,480	2,431	2,842	3,368	3,721	4,558	5,191
OPM %	23.52	22.68	25.85	27.34	30.98	28.58	29.54	31.39	32.31	32.61	33.02
Other Income	223	299	-300	121	57	-288	45	146	-0.94	-182	-179
Interest	206	308	504	451	353	255	333	354	252	385	634
Depreciation	307	409	618	654	658	662	707	808	795	1,119	1,511
Profit Before Tax	1,088	931	562	1,187	1,526	1,226	1,847	2,352	2,673	2,872	2,867
Tax %	14.20	27.16	22.32	13.64	17.98	36.60	32.59	29.58	28.49	25.56	24.80
Net Profit	934	678	436	1,025	1,252	777	1,245	1,656	1,911	2,138	2,156
EPS in Rs	27.59	20.04	12.89	30.28	36.99	22.97	36.78	48.94	56.47	64.01	64.01
Dividend Payout %	25.38	34.94	65.94	52.85	47.31	209.06	59.80	57.21	56.67	59.45	—

Consolidated Balance Sheet (in ₹ Crores)

View Standalone

Total Figures

YoY Changes

Total Figures

	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
Equity Capital	85	85	85	85	85	85	169	169	169	169
Reserves	4,266	4,538	4,640	4,739	5,753	5,868	6,029	6,687	7,421	8,219
Borrowings	2,241	5,737	4,847	4,366	4,874	4,070	5,369	4,022	3,202	15,026
Other Liabilities	3,111	3,884	4,550	4,820	3,363	3,077	3,445	4,182	4,197	20,898
Total Liabilities	9,702	14,243	14,121	14,010	14,075	13,100	15,012	15,061	14,990	44,312
Fixed Assets	3,688	7,855	7,748	7,533	7,065	6,423	8,121	8,138	7,947	33,178
CWIP	519	647	617	712	889	630	765	361	478	641
Investments	804	492	353	2.11	181	226	199	173	156	961
Other Assets	4,691	5,249	5,403	5,763	5,939	5,821	5,926	6,389	6,409	9,531
Total Assets	9,702	14,243	14,121	14,010	14,075	13,100	15,012	15,061	14,990	44,312

Consolidated Cash Flows (in ₹ Crores)

View Standalone

Total Figures

YoY Changes

Total Figures

	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
Cash from Operating Activity	1,009	894	1,798	1,393	2,005	1,803	2,368	3,266	2,585	3,023
Cash from Investing Activity	-787	-4,702	-241	199	-449	-197	-2,356	-168	-540	-12,712
Cash from Financing Activity	-193	3,417	-1,314	-1,549	-1,651	-1,781	77	-2,780	-2,298	10,151
Net Cash Flow	29	-390	242	42	-95	-175	89	319	-253	461

Shareholdings

Shareholding History

Quarterly

Yearly

Quarterly

	Dec 2023	Mar 2024	Jun 2024	Sep 2024	Dec 2024	Mar 2025	Jun 2025	Sep 2025	Dec 2025	Mar 2026	Jun 2026	Jul 2026
Promoters	71.25%	71.25%	71.25%	71.25%	68.31%	68.31%	68.31%	68.31%	68.31%	68.31%	68.31%	60.78%
FIIs	14.09%	14.14%	14.22%	14.46%	16.17%	16.31%	16.09%	15.92%	16.13%	16.18%	15.44%	17.97%
DIIs	7.21%	7.26%	7.27%	7.08%	8.35%	8.35%	8.66%	9.29%	9.15%	9.07%	9.83%	12.87%
Public	7.45%	7.36%	7.26%	7.21%	7.17%	7.03%	6.94%	6.49%	6.42%	6.45%	6.42%	8.38%
Total Shareholders	69,117	71,154	74,765	79,848	85,035	86,005	81,856	78,226	76,214	83,811	85,776	1,40,599

Market Transactions

Unlock more with professional

Real-time bulk & block deal transactions
Export transaction data for analysis

Projection

Unlock more with professional

Analyst Target, Price, EPS and Revenue Projections
Get In-depth insights on EPS and Revenue forecasts

Documents

Presentations

Concalls

Reports

Presentations

Investor Presentation

Q4 FY26

Investor Presentation

Q3 FY26

Investor Presentation

Q2 FY26

Investor Presentation

Q1 FY26

Investor Presentation

Q4 FY25

Investor Presentation

Q1 FY23

Investor Presentation

Q4 FY18

Investor Presentation

Q4 FY18

Showing 1 - 8 of 10

Actions

Action Type

‌
‌

Announcements

Last 7 days

Sentiment

Earnings Call/Transcript

22 hours ago

Torrent Pharmaceuticals Q1 Concall Audio Posted

Torrent Pharmaceuticals Ltd posted the audio recording of the analysts/investors conference call on financial results for the quarter ended 30 June 2026 on its website.

Earnings Call/Transcript

22 hours ago

Torrent Pharmaceuticals Q1 Concall Audio Recording

Torrent Pharmaceuticals Ltd has placed the audio recording of the Analysts/Investors conference call on financial results for the quarter ended 30 June 2026 on its website.

Change in Directors/KMP

1 day ago

Torrent Pharmaceuticals Ltd: Change in Senior Management

Torrent Pharmaceuticals Ltd notified that Hasmukh Patel, Sushil Jaiswal and Sunil Nadkarni ceased to be Senior Management Personnel effective 30-07-2026 due to a change in reporting structure.

Change in Directors/KMP

1 day ago

Torrent Pharmaceuticals - Change in Senior Management

Torrent Pharmaceuticals Ltd informed exchanges that Hasmukh Patel, Sushil Jaiswal and Sunil Nadkarni ceased to be part of Senior Management w.e.f. 30-07-2026 due to change in reporting structure.

Financial Results

1 day ago

Torrent Pharma approves Q1 FY27 results

Torrent Pharmaceuticals Ltd approved unaudited standalone and consolidated financial results for quarter ended 30 June 2026 with limited review; press release enclosed. Independent Director Ameera Shah to complete term on 01-08-2026.

Financial Results

1 day ago

Torrent Pharmaceuticals approves Q1 FY27 results

Torrent Pharmaceuticals' Board approved unaudited standalone and consolidated financial results for quarter ended 30 June 2026 with limited review; press release enclosed. Independent director Ameera Shah to complete term on 01-08-2026.

Showing 1 - 6 of 11

AI Mode

Ask AI

Frequently Asked Questions about Torrent Pharmaceuticals Ltd

Torrent Pharmaceuticals Ltd (TORNTPHARM) is currently trading at 5,130.00 per share. Stock prices fluctuate during market hours on NSE and BSE based on demand, company updates, and overall market conditions. Refer to the live price chart above for the most recent price movement.

Torrent Pharmaceuticals is an India‑headquartered, vertically integrated pharmaceutical company focused on branded chronic and sub‑chronic therapies, with a diversified international presence across the US, Europe (Germany) and Latin America (Brazil) and over 15 country subsidiaries supporting formulation manufacturing, R&D and commercial operations for both regulated and emerging markets. In Q3 FY26 Torrent reported consolidated revenues of INR 3,303 crore, up 18% year‑on‑year, with Operating EBITDA of INR 1,088 crore and an operating margin of 32.9%. Branded markets contributed roughly 75% of revenues; India grew 14% and Brazil grew 27%, while the U.S. and Germany contributed double‑digit and modest growth respectively amid some supply constraints. Torrent acquired a controlling stake in JB Pharma in January and began line‑by‑line consolidation; management expects INR 400–450 crore of cost synergies over 2–3 years (20% in year one, majority thereafter) and a 6–9 month timeline to integrate post NCLT merger, making the JB acquisition a material near‑term strategic catalyst for the company. Brazil represents a high‑conviction growth opportunity with a prioritized Semaglutide (GLP‑1) filing; management reports ANVISA prioritization and a 60‑molecule pipeline, but cautions on unpredictable approval timing and potential pricing erosion, which could meaningfully influence Brazilian revenue upside upon launch. Near‑term operational risks include regulatory and third‑party supplier disruptions in Germany that depressed constant‑currency sales; the U.S. business is small but supported by a launch pipeline with management targeting annualized U.S. revenues near $200 million over the medium term, contingent on timely approvals and competitive dynamics.

Over the past 52 weeks, Torrent Pharmaceuticals Ltd has traded between a low of ₹3,480.00 and a high of ₹5,084.85. The 52-week high and low indicate the stock’s price range over the last year and help investors understand its volatility and recent trading levels.

Torrent Pharmaceuticals Ltd has a market capitalization of approximately 1,85,263.87. Market capitalization represents the total value of a company’s outstanding shares and helps investors understand its size, stability, and relative risk compared to other listed companies.

Torrent Pharmaceuticals Ltd’s investment profile depends on its business fundamentals, valuation, and long-term outlook. The stock currently trades at a PE ratio of 86.65 and operates in the its sector sector. Investors typically assess financial performance, growth prospects, and individual risk tolerance before making investment decisions.

Based on its market capitalization of 1,85,263.87 Cr, Torrent Pharmaceuticals Ltd is classified as a Large Cap stock. Large-cap stocks are generally more stable, while mid-cap and small-cap stocks tend to offer higher growth potential along with higher price volatility.

Torrent Pharmaceuticals Ltd operates in the its sector sector. Sector classification matters because companies in the same sector are often affected by similar economic conditions, regulatory changes, and competitive dynamics, which can influence overall stock performance.

The Price-to-Earnings (PE) ratio of Torrent Pharmaceuticals Ltd is 86.65. The PE ratio compares a company’s share price to its earnings and is commonly used to assess valuation. Comparing the PE ratio with sector peers and historical levels provides better context.

Revenue rose 11% year-on-year to INR 3,178 crore, while consolidated net profit increased about 20% to INR 548 crore for the quarter ended June 2025.

Torrent Pharma said the USFDA inspected its Dahej, Gujarat facility from January 19-23, 2026 and the inspection concluded with zero observations and no Form 483 issued.

Torrent Pharmaceuticals said the amalgamation became effective on July 8, 2026, after filing certified copies of the NCLT order with the Registrar of Companies.

J.B. Pharma shareholders will receive 51 Torrent Pharma shares for every 100 J.B. Pharma shares held, as stated in the approved scheme.

Torrent Pharmaceuticals Ltd

Actions

AI Mode

Ask AI

Investor's Suite

Market Explorer

Market Pulse

Deep Dive

Utility

Company

Overview

Financial Ratios

Technicals

Forecasts

Unlock more with professional

Peers

Price Chart Comparison

Financial Statements

AI Powered Summary

Ask AI

Consolidated Quarterly Results (in ₹ Crores)

Consolidated Profit Loss (in ₹ Crores)

Consolidated Balance Sheet (in ₹ Crores)

Consolidated Cash Flows (in ₹ Crores)

Shareholdings

Shareholding History

Market Transactions

Unlock more with professional

Projection

Unlock more with professional

Documents

Actions

Announcements

Torrent Pharmaceuticals Q1 Concall Audio Posted

Torrent Pharmaceuticals Q1 Concall Audio Recording

Torrent Pharmaceuticals Ltd: Change in Senior Management

Torrent Pharmaceuticals - Change in Senior Management

Torrent Pharma approves Q1 FY27 results

Torrent Pharmaceuticals approves Q1 FY27 results

AI Mode

Ask AI

Frequently Asked Questions about Torrent Pharmaceuticals Ltd

What is Torrent Pharmaceuticals Ltd share price today?

What does Torrent Pharmaceuticals Ltd do?

What is the 52-week high and low of Torrent Pharmaceuticals Ltd?

What is the market capitalization of Torrent Pharmaceuticals Ltd?

Should I consider investing in Torrent Pharmaceuticals Ltd stock?

Is Torrent Pharmaceuticals Ltd a large-cap, mid-cap, or small-cap stock?

Which sector does Torrent Pharmaceuticals Ltd belong to and why does it matter?

What is the PE ratio of Torrent Pharmaceuticals Ltd?

What were Torrent Pharmaceuticals’ Q1 FY26 revenue and profit numbers?

What did Torrent Pharma say about the USFDA inspection at its Dahej plant?

What is the effective date of the Torrent Pharma and J B Chemicals merger?

What is the share-swap ratio for the J.B. Pharma and Torrent Pharma amalgamation?

Technicals

Documents

Stock Summary and Key Metrics

Investment Checklist

Investment Checklist

Forecasts

Unlock more with professional

Projection

Unlock more with professional

Shareholdings

Shareholding History

Market Transactions

Unlock more with professional

Overview

Financial Ratios

Investment Checklist

Peers

Price Chart Comparison

Financial Statements

AI Powered Summary

Ask AI

Consolidated Quarterly Results (in ₹ Crores)

Consolidated Profit Loss (in ₹ Crores)

Consolidated Balance Sheet (in ₹ Crores)

Consolidated Cash Flows (in ₹ Crores)

Frequently Asked Questions about Torrent Pharmaceuticals Ltd